Clinical trials: Cardiometabolic Risk
Coronary Artery Disease
Cardiometabolic Risk in Cardiac Rehab
1. Primary Objectives: To characterize cardiometabolic risk factor profiles of patients entering cardiac rehab using traditional approaches (eg LDL-C) as well as a more comprehensive panel of cardiovascular and metabolic…
- Trial name
- NCT01985048
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- Health Diagnostic Laboratory, Inc.
Obesity
High Density Lipoprotein Turnover
The objective of the study is to evaluate the effect of Rimonabant 20mg in comparison to placebo, on HDL and VLDL lipoprotein kinetics, over a 12 months period.
- Trial name
- NCT00408148
- Testing
- Rimonabant
- Where
- 4 sites in Australia, Finland and 2 more
- Volunteers
- 64 people
- Sponsor
- Sanofi
Overweight and Obesity, Dyslipoproteinemia
Effect of Weight Management Programs on Cardiometabolic Risk Profile in Overweight Women
Aim of this prospective randomized study was to evaluate whether a diet with meal replacements can be as effective as a conventional energy-restricted modified diet on weight loss, body composition and cardiometabolic risk…
- Trial name
- FM-01 (NCT03109834)
- Testing
- Meal replacement (MR), Control (C), Verum
- Volunteers
- 105 people
- Sponsor
- Bonn Education Association for Dietetics r.A., Cologne, Germany
Metabolic Cardiovascular Syndrome
Hyperinsulinemic Euglycemic Clamp Protocol
The purpose of the study is to determine the safety and efficacy of TRC150094 in male patients with cardiometabolic risk. Cardiometabolic risk which is the overall risk of cardiovascular disease (CVD) and diabetes resulting from…
- Trial name
- NCT01408667
- Testing
- TRC150094
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Torrent Pharmaceuticals Limited
Psoriasis, Inflammation
A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors
The primary purpose of this proof-of-activity, phase 2 trial is to evaluate the safety and activity of orticumab in subjects with moderate to severe psoriasis and cardiometabolic risk factors.
- Conditions
- Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
- Trial name
- NCT04776629
- Testing
- Orticumab
- Where
- 13 sites in United States
- Volunteers
- 77 people
- Sponsor
- Abcentra
Obesity, Microalbuminuria
Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors
Primary objective: To assess the effect on microalbuminuria levels of treatment with rimonabant 20 mg versus a placebo during a 12 month period.
- Conditions
- Obesity, Microalbuminuria, Diabetes Mellitus, Type 2, Dyslipidemia
- Trial name
- RIALTO (NCT00458081)
- Testing
- Rimonabant
- Where
- Spain
- Volunteers
- 174 people
- Sponsor
- Sanofi
Overweight, Obesity
Individual Factors Related to Chronic Low-grade Inflammation and Cardiometabolic Disease Risk
The goal of this observational study is to learn about low-grade inflammation in healthy individuals and individuals with overweight or obesity.
- Conditions
- Overweight, Obesity, Metabolic Syndrome, Healthy
- Trial name
- PINEAPPL (NCT06355544)
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Integrative Phenomics
Acute Myocardial Infarction, Heart Failure
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for hospitalisation for heart failure (HHF)…
- Trial name
- DAPA-MI (NCT04564742)
- Testing
- Dapagliflozin
- Where
- 103 sites in Sweden, United Kingdom
- Volunteers
- 4,017 people
- Sponsor
- AstraZeneca
Age-related Cognitive Decline
Study on the Chronic and Acute Effects of Nordic Berry Beverage on Cognitive Function
The aim of the current study is to investigate whether acute and 12-weeks daily intake of Nordic berries can improve cognitive abilities of adults without cognitive disease, and whether the effect can be linked to changes in…
- Trial name
- SCANBerry (NCT05693441)
- Testing
- Active berry product, Reference berry-like product
- Where
- Sweden
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Aventure AB
Type II Diabetes Mellitus, Obesity
A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics
One out of two adults in Canada is currently overweight and therefore at increased risk for a number of medical conditions including diabetes, high blood pressure, heart attacks and stroke.
- Trial name
- NCT01644201
- Testing
- PolyGlycopleX® - PGX®
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- InovoBiologic Inc.
PHYSIOLOGICAL PHENOMENA, Homeostasis
Truway Whole-Body Digital Twin and Physiologic Resilience Study (TRU-OMNIBODY)
TRU-OMNIBODY is a prospective observational study designed to develop and independently validate a research-only whole-body digital twin.
- Conditions
- PHYSIOLOGICAL PHENOMENA, Homeostasis, Physical Functional Performance, Cardiorespiratory Fitness
- Trial name
- TRU-OMNIBODY (NCT07805044)
- Testing
- Standardized Physiologic Resilience Challenge, Multimodal Whole-Body Physiologic Monitoring, Research-Only Whole-Body Digital Twin Analysis
- Where
- United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
Glycemic Response
Avocado Fruit on Postprandial Markers of the Glycemic Response, Satiety/Appetite and Cardiometabolic Risk
The primary goal is to characterize the acute effects of avocado intake on glycemic and satiety/ appetite responses in relatively healthy overweight / obese adults.
- Trial name
- AVOC1 (NCT02479048)
- Testing
- Test meal 1, Test meal 2, Control Meal (CM)
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Non-Alcoholic Fatty Liver Disease
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content, cardiometabolic risk factors and gut microbiota…
- Trial name
- CARDIO-LIVER (NCT06704321)
- Testing
- TOTUM-448
- Where
- Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Pre-diabetes, Diabetes Mellitus
Artificial Intelligence to Improve Cardiometabolic Risk Evaluation Using CT Scans
To validate the ability of the FatHealth algorithm to identify individuals with pre-diabetes and with type 2 diabetes mellitus
- Trial name
- ACRE-CT (NCT05058690)
- Testing
- Oral Glucose Tolerance Test
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Caristo Diagnostics Limited
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Hypertension, Pre Diabetes
MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors
Inflammation and stressors can interfere with the function of the lining of blood vessels and insulin activity, therefore, investigators are aiming to see how the Grape seed Extract (GSE) called MegaNatural BP can help with…
- Trial name
- GSEBP (NCT06555952)
- Testing
- MegaNatural-BP SR 150Mg Tablet
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Metabolic Syndrome, Overweight
Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome
The objective of this study was to investigate from 3 sites (University of Connecticut, University of Florida, and University of California, Irvine) whether enhancement of a modified Mediterranean-style, low glycemic load diet…
- Conditions
- Metabolic Syndrome, Overweight, Obesity, Hypercholesterolemia
- Trial name
- HMS4 (NCT01010841)
- Testing
- UltraMealPlus 360 (Medical food), Low-glycemic-load diet
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- MetaProteomics LLC